Abuse and alcohol resistant drug composition
A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, surfactants and stabilizers. The composition and physicochemical properties makes it harder or prevents dose dumping of narcotic analgesics in the presence of alcohol and harder to abuse opiod agonists or narcotic analgesics and discourages drug abuse via crushing, milling or grinding the dosage form to powder or heating the dosage form to vapour and snorting or inhalation by the nasal route or dissolving to abuse via the parenteral route.
1. A pharmaceutical composition comprising:
(i) an active pharmaceutical agent selected from the group consisting of an opioid and an opiate; and
(ii) 40-50% by weight of an oil selected form the group consisting of almond oil, canola oil, castor oil, corn oil, cottonseed oil, mineral oil, olive oil, olive-pomace oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, and mixtures thereof; and
(iii) at least 15% by weight of a controlled-release agent selected from the group consisting of hydroxypropyl methylcellulose (hypromellose), hydroxypropyl cellulose, and polyethylene oxide,
wherein the composition is a non-aqueous paste.
2. The pharmaceutical composition of claim 1 , wherein (1) the pharmaceutical composition further comprises a clay mineral and (2) the clay mineral is 0.5-20% by weight of the pharmaceutical composition.
3. The pharmaceutical composition of claim 2 , wherein the clay mineral is bentonite.
4. The pharmaceutical composition of claim 3 , wherein bentonite is 1.0-2.5% by weight of the pharmaceutical composition.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises bentonite.
6. The pharmaceutical composition of claim 1 , wherein the controlled-release agent is hydroxypropyl methylcellulose (hypromellose).
7. The pharmaceutical composition of claim 6 , wherein the hydroxypropyl methylcellulose (hypromellose) is 18-22% by weight of the pharmaceutical composition.
8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises a carbomer.
9. The pharmaceutical composition of claim 8 , wherein the carbomer is 5-8% by weight of the pharmaceutical composition.
10. The pharmaceutical composition of claim 1 , wherein the active pharmaceutical agent is an opioid selected from the group consisting of oxycodone and tramadol.
11. The pharmaceutical composition of claim 10 , wherein the opioid is oxycodone.
12. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is on a structure.
13. The pharmaceutical composition of claim 12 , wherein the structure is a transdermal patch.
14. A pharmaceutical composition comprising:
(i) an active pharmaceutical agent selected from the group consisting of an opioid and an opiate; and
(ii) 3-50% by weight of an oil selected form the group consisting of almond oil, canola oil, castor oil, corn oil, cottonseed oil, mineral oil, olive oil, olive-pomace oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, and mixtures thereof; and
(iii) at least 15% by weight of a controlled-release agent selected from the group consisting of hydroxypropyl methylcellulose (hypromellose), hydroxypropyl cellulose, and polyethylene oxide; and
(iv) a carbomer, wherein the carbomer is at least 5% by weight of the pharmaceutical composition but less than or equal to 8% by weight of the pharmaceutical composition,
wherein the composition is a non-aqueous paste.
15. The pharmaceutical composition of claim 14 , wherein (1) the pharmaceutical composition further comprises a clay mineral and (2) the clay mineral is 0.5-20% by weight of the pharmaceutical composition.
16. The pharmaceutical composition of claim 15 , wherein the clay mineral is bentonite.
17. The pharmaceutical composition of claim 16 , wherein bentonite is 1.0-2.5% by weight of the pharmaceutical composition.
18. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition further comprises bentonite.
19. The pharmaceutical composition of claim 14 , wherein the controlled-release agent is hydroxypropyl methylcellulose (hypromellose).
20. The pharmaceutical composition of claim 19 , wherein the hydroxypropyl methylcellulose (hypromellose) is 18-22% by weight of the pharmaceutical composition.
21. The pharmaceutical composition of claim 14 , wherein the carbomer is 8% by weight of the pharmaceutical composition.
22. The pharmaceutical composition of claim 14 , wherein the active pharmaceutical agent is an opioid selected from the group consisting of oxycodone and tramadol.
23. The pharmaceutical composition of claim 22 , wherein the opioid is oxycodone.
24. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition is on a structure.
25. The pharmaceutical composition of claim 24 , wherein the structure is a transdermal patch.
26. A pharmaceutical composition comprising:
(i) an active pharmaceutical agent selected from the group consisting of an opioid and an opiate; and
(ii) 40-50% by weight of an oil selected form the group consisting of almond oil, canola oil, castor oil, corn oil, cottonseed oil, mineral oil, olive oil, olive-pomace oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, and mixtures thereof;
(iii) at least 15% by weight of a controlled-release agent comprising hydroxypropyl methylcellulose (hypromellose); and
(iv) 0.5-20% by weight of a clay mineral;
wherein the composition is a non-aqueous paste.